LANTHEUS HOLDINGS,INC. (NASDAQ:LNTH) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07

The Annual Meeting of Stockholders (the Annual Meeting) of
Lantheus Holdings, Inc. (the Company) was held on April27, 2017.
Set forth below is a brief description of each matter submitted
to a vote of the Companys stockholders at the Annual Meeting and
the final voting results for each matter. A more complete
description of each matter is set forth in the Companys
definitive proxy statement for the Annual Meeting, which was
filed with the Securities and Exchange Commission on March17,
2017.

Proposal 1 Election of Directors

Each of the following nominees for ClassII director was elected
by the Companys stockholders to serve a three-year term until the
2020 Annual Meeting of Stockholders based on the following vote:

Proposal 2 Approval of Amendment to Lantheus Holdings, Inc.
2015 Equity Incentive Plan

The Amendment to the Lantheus Holdings, Inc. 2015 Equity
Incentive Plan to increase the number of shares of common stock
reserved for issuance thereunder by 1,200,000 shares was approved
by the Companys stockholders based on the following vote:

Proposal 3 Approval of Lantheus Holdings, Inc. 2017 Employee
Stock Purchase Plan

The Lantheus Holdings, Inc. 2017 Employee Stock Purchase Plan was
approved by the Companys stockholders based on the following
vote:

Proposal 4 Ratification of Appointment of Deloitte Touch
LLP

The appointment of Deloitte Touche LLP as the Companys
independent registered public accounting firm for the fiscal year
ending December31, 2017 was ratified by the Companys stockholders
based on the following vote:

(d) Exhibits

About LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH)

Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.

LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) Recent Trading Information

LANTHEUS HOLDINGS, INC. (NASDAQ:LNTH) closed its last trading session up +0.15 at 13.00 with 435,277 shares trading hands.